Try our beta test site
319 studies found for:    cml | United States
Show Display Options
Rank Status Study
1 Active, not recruiting Symptom Burden in Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Interventions: Behavioral: Interview & Questionnaires;   Behavioral: Rating Questionnaire;   Behavioral: MDASI-CML Questionnaire
2 Terminated Reduced Intensity AlloSCT in(CML) With Persistent Disease
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Reduced Intensity Conditioning, Busulfan and Fludarabine
3 Recruiting Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
4 Completed Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
Condition: Chronic Myeloid Leukemia (CML)
Intervention:
5 Terminated
Has Results
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Conditions: Myeloid Leukemia, Chronic;   Myeloid Leukemia, Chronic, Accelerated-Phase;   Blast Phase;   Myeloid Leukemia, Chronic, Chronic-Phase
Interventions: Drug: Homoharringtonine;   Drug: Imatinib Mesylate
6 Completed PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Conditions: Acute Myelogenous Leukemia;   Agnogenic Myeloid Metaplasia;   Chronic Myelogenous Leukemia
Interventions: Drug: Imatinib Mesylate (Gleevec);   Drug: PTK 787 (vatalanib)
7 Completed
Has Results
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Condition: Leukemia
Interventions: Biological: GM-CSF;   Biological: Interferon-α-2b
8 Active, not recruiting Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Condition: Leukemia, Myelogenous, Chronic
Intervention: Drug: Nilotinib
9 Active, not recruiting Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
10 Completed Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
Condition: Myelogenous Leukemia, Chronic
Intervention: Drug: SCH66336
11 Recruiting Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
12 Terminated Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
Condition: Myelogenous Leukemia, Chronic, Chronic Phase
Intervention: Drug: Gleevec
13 Completed Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Conditions: Stem Cell Transplantation;   Leukemia
Interventions: Drug: Fludarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Drug: Azacitidine;   Procedure: Stem Cell Transplant
14 Recruiting Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML)
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Bosutinib;   Behavioral: Phone Calls;   Behavioral: Questionnaires
15 Completed Therapy of Early Chronic Phase CML With Gleevec
Condition: Leukemia, Myeloid, Chronic-Phase
Intervention: Drug: Gleevec
16 Recruiting Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
Condition: Leukemia
Interventions: Drug: Axitinib;   Drug: Bosutinib
17 Recruiting Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)
Conditions: Leukemia;   Chronic Myeloid Leukemia;   Myelofibrosis
Intervention: Drug: Eltrombopag
18 Completed
Has Results
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
Conditions: Chronic Myeloid Leukemia;   Minimal Residual Disease
Intervention: Biological: Synthetic Tumor-Specific Breakpoint Peptide Vaccine
19 Not yet recruiting Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
20 Completed Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease
Condition: Leukemia
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.